https://www.thebodypro.com/category/fda-approved-hiv-medications/tag/conference-coverage
FDA-Approved HIV Medications

Conference Coverage

The Latest

Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

Christoph D. Spinner

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring Img

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

Promo Image

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Promo Image

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study Img

Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study

Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.

Bictegravir in the Body -- Preliminary Information About Drug Interactions Img

Bictegravir in the Body -- Preliminary Information About Drug Interactions

The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.

Promo Image

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.